Immune globulins and thrombotic adverse events as recorded in a large administrative database in 2008 through 2010

Transfusion

Volumn 52, Issue 10, 2012, Pages 2113-2121

  Daniel, Gregory W ^a   Menis, Mikhail ^a   Sridhar, Gayathri ^a   Scott, Dorothy ^a   Wallace, Anna E ^a   Ovanesov, Mikhail V ^a   Golding, Basil ^a   Anderson, Steven A ^a   Epstein, Jay ^a   Martin, David ^a   Ball, Robert ^a   Izurieta, Hector S ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G;

ADULT; ARTICLE; COHORT ANALYSIS; COMORBIDITY; DATA BASE; DYSLIPIDEMIA; FEMALE; GAMMOPATHY; HEALTHCARE COMMON PROCEDURE CODING SYSTEM; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OBESITY; RETROSPECTIVE STUDY; RISK FACTOR; THROMBOSIS;

ADOLESCENT; ADULT; AGE FACTORS; AGED; BLUE CROSS BLUE SHIELD INSURANCE PLANS; CHILD; COMORBIDITY; DATABASES, FACTUAL; DISEASE SUSCEPTIBILITY; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; IMMUNOGLOBULINS, INTRAVENOUS; INFLAMMATION; INTERNATIONAL CLASSIFICATION OF DISEASES; MALE; MIDDLE AGED; OBESITY; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOPHILIA; THROMBOSIS; UNITED STATES; YOUNG ADULT;

EID: 84868303959     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2012.03589.x     Document Type: Article

References (46)

1. Carbone J,. Adverse reactions and pathogen safety of intravenous immunoglobulin. Curr Drug Saf 2007; 2: 9-18.
2. Foster R, Suri A, Filate W, Hallett D, Meyer J, Ruijs T, Callum JL, Sutton D, Mehta S,. Use of intravenous immune globulin in the ICU: a retrospective review of prescribing practices and patient outcomes. Transfus Med 2010; 20: 403-8.
3. Hamrock DJ,. Adverse events associated with intravenous immunoglobulin therapy. Int Immunopharmacol 2006; 6: 535-42.
4. Katz U, Shoenfeld Y,. Review: intravenous immunoglobulin therapy and thromboembolic complications. Lupus 2005; 14: 802-8.
5. Katz U, Achiron A, Sherer Y, Shoenfeld Y,. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev 2007; 6: 257-9.
6. Kazatchkine MD, Kaveri SV,. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345: 747-55.
7. Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, Buckley R, Chinen J, El Gamal Y, Mazer BD, Nelson RP Jr, Patel DD, Secord E, Sorensen RU, Wasserman RL, Cunningham-Rundles C,. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006; 117: S525-S553.
8. Pierce LR, Jain N,. Risks associated with the use of intravenous immunoglobulin. Transfus Med Rev 2003; 17: 241-51.
9. Leong H, Stachnik J, Bonk ME, Matuszewski KA,. Unlabeled uses of intravenous immune globulin. Am J Health Syst Pharm 2008; 65: 1815-24.
10. Orbach H, Katz U, Sherer Y, Shoenfeld Y,. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol 2005; 29: 173-84.
11. Marie I, Maurey G, Herve F, Hellot MF, Levesque H,. Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature. Br J Dermatol 2006; 155: 714-21.
12. Paran D, Herishanu Y, Elkayam O, Shopin L, Ben Ami R,. Venous and arterial thrombosis following administration of intravenous immunoglobulins. Blood Coagul Fibrinolysis 2005; 16: 313-8.
13. Brown HC, Ballas ZK,. Acute thromboembolic events associated with intravenous immunoglobulin infusion in antibody-deficient patients. J Allergy Clin Immunol 2003; 112: 797-9.
14. Stein MR,. The new generation of liquid intravenous immunoglobulin formulations in patient care: a comparison of intravenous immunoglobulins. Postgrad Med 2010; 122: 176-84.
15. Dalakas MC,. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology 1994; 44: 223-6.
16. Reinhart WH, Berchtold PE,. Effect of high-dose intravenous immunoglobulin therapy on blood rheology. Lancet 1992; 339: 662-4.
17. Wolberg AS, Kon RH, Monroe DM, Hoffman M,. Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. Am J Hematol 2000; 65: 30-4.
18. Alving BM, Tankersley DL, Mason BL, Rossi F, Aronson DL, Finlayson JS,. Contact-activated factors: contaminants of immunoglobulins preparations with coagulant and vasoactive properties. J Lab Clin Med 1980; 96: 334-46.
19. Etscheid M, Breitner-Ruddock S, Gross S, Hunfeld A, Seitz R, Dodt J,. Identification of kallikrein and FXIa as impurities in therapeutic immunoglobulins: implications for the safety and control of intravenous blood products. Vox Sang 2012; 102: 40-6.
20. Marzo N, Jose M, Lopez L, Bono M, Lopez M, Jorquera JL,. Quantitative determination of relevant amounts of blood coagulation factor XI acitivity in a specific brand of intravenous immunoglobulin. WebmedCentral Immunotherapy. 2011; 2: WMC001922.
21. European Medicines Agency. European Medicines Agency recommends suspension of Octagam in all EU Member States; September 24, 2010. [cited 2010 Dec 28]. European Medicines Agency Press Release. Available from: URL: http://www.ema.europa.eu/docs/en-GB/document-library/Press-release/2010/09/ WC500097037.pdf
22. Urgent Voluntary Product Recall. Omr-IgG-am 5% IV, Registration Number 127543069800-ALL LOTS. Omrix Biopharmaceuticals. 2010. [cited 2010 Nov 7]. Available from: URL: http://www.omrix.com/ IVIG%20HepB%20Combined%20Voluntary%20Recall%20Dr%20Doctor%20FINAL.pdf
23. Recalls (Biologics). URGENT: Voluntary Market Withdrawal-September 23, 2010 Octagam [Immune Globulin Intravenous (Human)] 5% Liquid Preparation. Center for Biologics and Research, FDA. 2010. [cited 2010 Dec 28]. Available from: URL: http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/Recalls/ ucm227133.htm
24. Ramagopalan SV, Wotton CJ, Handel AE, Yeates D, Goldacre MJ,. Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage study. BMC Med 2011; 9: 1.
25. Baser O, Palmer L, Stephenson J,. The estimation power of alternative comorbidity indices. Value Health 2008; 11: 946-55.
26. Elixhauser A, Steiner C, Harris DR, Coffey RM,. Comorbidity measures for use with administrative data. Med Care 1998; 36: 8-27.
27. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA,. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005; 43: 1130-9.
28. Deyo RA, Cherkin DC, Ciol MA,. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45: 613-9.
29. Ovanesov MV, Shibeko AM, Woodle SA, Anderson CM, Hogwood J, Barson H, Gray E, Scott D,. Association of factor XIa with intravenous immune globulin products implicated in thrombotic adverse events: biochemical root cause investigation. J Thromb Haemost 2011; 9 (Suppl 2): 272, O-TU-039.
30. Ovanesov MV,. Laboratory investigations of products associated with thrombotic events. FDA Workshop: Risk Mitigation Strategies to Address Procoagulant Activity in Immune Globulin Products. 2011. [cited 2011 May 17]. Available from: URL: http://www.fda.gov/downloads/BiologicsBloodVaccines/ NewsEvents/WorkshopsMeetingsConferences/UCM260788.pdf
31. Roemisch JR, Kaar W, Zoechling A, Kannicht C, Putz M, Kohla G,. Identification of activated FXI as the major biochemical root cause in IVIG batches associated with thromboembolic events. Analytical and experimental approaches resulting in corrective and preventive measures implemented into the Octagam® manufacturing process. WebmedCentral Immunotherapy. 2011; 2: WMC002002.
32. Gross S, Funk M, Keller-Stanislawski B,. IG-associated thrombotic adverse events-Pharmacovigilance. Public Workshop: Risk Mitigation Strategies to Address Potential Procoagulant Activity in Immune Globulin Products. May 17-18, 2011, Rockville, Maryland. [cited 2011 Dec 13]. Available from: URL: http://www.fda.gov/downloads/BiologicsBloodVaccines/NewsEvents/ WorkshopsMeetingsConferences/UCM260769.pdf
33. US Food and Drug Administration, Center for Biologics Evaluation and Research. Important safety information: risk of thrombotic adverse events with subcutaneous or inappropriate intravenous use of Vivaglobin (immune globulin subcutaneous). 2011. [cited 2011 Mar 11]. Available from: URL: http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ucm246863.htm
34. Schulte S,. Characterization of proteolytical activity in IgG-Vivaglobin. Public Workshop: Risk Mitigation Strategies to Address Potential Procoagulant Activity in Immune Globulin Products. May 17-18, 2011, Rockville, Maryland. [cited 2011 Dec 20]. Available from: URL: http://www.fda.gov/downloads/ BiologicsBloodVaccines/NewsEvents/WorkshopsMeetingsConferences/UCM260780.pdf
35. Bolton-Maggs PH, Colvin BT, Satchi BT, Lee CA, Lucas GS,. Thrombogenic potential of factor XI concentrate. Lancet 1994; 344: 748-9.
36. Gitel SN, Varon D, Schulman S, Martinowitz U,. Clinical experiences of a FXI-concentrate: possible side effects. Thromb Haemost 1991; 65: 1157.
37. Mannucci PM, Bauer KA, Santagostino E, Faioni E, Barzegar S, Coppola R, Rosenberg RD,. Activation of the coagulation cascade after infusion of a factor XI concentrate in congenitally deficient patients. Blood 1994; 84: 1314-9.
38. Richards EM, Makris MM, Cooper P, Preston FE,. In vivo coagulation activation following infusion of highly purified factor XI concentrate. Br J Haematol 1997; 96: 293-7.
39. Caress JB, Cartwright MS, Donofrio PD, Peacock JE Jr,. The clinical features of 16 cases of stroke associated with administration of IVIg. Neurology 2003; 60: 1822-4.
40. Haplea SS, Farrar JT, Gibson GA, Larkin M, Pizzi LT, Asbury AK,. Thromboembolic events associated with intravenous immunoglobulin therapy. Neurology 1997; 48: A54.
41. Huang L, Kanellis J, Mulley W,. Slow and steady. Reducing thrombotic events in renal transplant recipients treated with IVIg for antibody-mediated rejection. Nephrology (Carlton) 2011; 16: 239-42.
42. Stangel M, Hartung HP, Marx P, Gold R,. Side effects of high-dose intravenous immunoglobulins. Clin Neuropharmacol 1997; 20: 385-93.
43. Wittstock M, Benecke R, Zettl UK,. Therapy with intravenous immunoglobulins: complications and side-effects. Eur Neurol 2003; 50: 172-5.
44. Meijers JC, Tekelenburg WL, Bouma BN, Bertina RM, Rosendaal FR,. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med 2000; 342: 696-701.
45. Caress JB, Hobson-Webb L, Passmore LV, Finkbiner AP, Cartwright MS,. Case-control study of thromboembolic events associated with IV immunoglobulin. J Neurol 2009; 256: 339-42.
46. US Food and Drug Administration. Safety alerts for human medical products: immune globulin intravenous (human) [IGIV]. 2002. [cited 2011 Jan 5]. Available from: URL: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm154633.htm